Aclaris director awarded RSUs and stock options

Aclaris Therapeutics director Vincent Milano reported equity compensation activity.

Rhea-AI Filing Summary

Aclaris Therapeutics director Vincent Milano reported equity compensation activity. On June 5, 2026, 11,580 restricted stock units vested and were settled into the same number of common shares, bringing his direct common stock holdings to 28,896 shares.

On June 4, 2026, he received 10,987 new restricted stock units that are scheduled to vest in one installment on June 4, 2027, and a grant of 42,350 stock options with a $4.71 exercise price, vesting in twelve equal monthly installments starting July 4, 2026, under Aclaris’s non-employee director compensation policy and 2025 Equity Incentive Plan.

Insider Trade Summary

11,580 shares exercised/converted

Exercise 4 txns

Insider MILANO VINCENT

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,580	$0.00	$0.00
Exercise	Common Stock	11,580	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	42,350	$0.00	$0.00
Grant/Award	Restricted Stock Units	10,987	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 42,350 contracts (Direct); Restricted Stock Units — 10,987 contracts (Direct); Common Stock — 28,896 shares (Direct)

Footnotes (5)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2. F2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
3. F3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
4. F4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
5. F5. The shares underlying these restricted stock units vested on June 5, 2026.

Key Figures

Common shares from RSU vesting: 11,580 shares Common shares held after transactions: 28,896 shares New RSU grant: 10,987 units +2 more

5 metrics

Common shares from RSU vesting 11,580 shares RSUs vested and converted on June 5, 2026

Common shares held after transactions 28,896 shares Direct holdings following June 5, 2026 activity

New RSU grant 10,987 units Granted June 4, 2026; scheduled to vest June 4, 2027

Stock option grant size 42,350 options Granted June 4, 2026 to purchase Aclaris common stock

Stock option exercise price $4.71 per share Conversion or exercise price for options expiring June 3, 2036

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), Continuous Service, 2025 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) for 42,350 shares with a $4.71 exercise price"

Continuous Service financial

"subject to the Reporting Person's Continuous Service as defined in the Issuer's 2025 Equity Incentive Plan"

2025 Equity Incentive Plan financial

"as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan"

non-employee director compensation policy financial

"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aclaris Therapeutics (ACRS) director Vincent Milano report on this Form 4?

Vincent Milano reported routine equity compensation activity. Previously granted restricted stock units vested into 11,580 common shares, and he received new grants of restricted stock units and stock options as part of Aclaris’s non-employee director compensation program.

How many Aclaris (ACRS) shares does Vincent Milano hold after these transactions?

After the reported transactions, Vincent Milano directly holds 28,896 shares of Aclaris Therapeutics common stock. This reflects settlement of 11,580 vested restricted stock units into common shares, with no open-market buying or selling disclosed in this Form 4.

What new restricted stock units did Vincent Milano receive from Aclaris (ACRS)?

On June 4, 2026, Vincent Milano received 10,987 restricted stock units, each representing one Aclaris common share. According to the filing, these units are scheduled to vest in a single installment on June 4, 2027, subject to his continued service with the company.

What are the terms of the new stock options granted to Vincent Milano by Aclaris (ACRS)?

Milano was granted options for 42,350 Aclaris common shares at a $4.71 exercise price. These options vest in twelve equal monthly installments starting July 4, 2026, and expire on June 3, 2036, aligning with Aclaris’s non-employee director compensation policy.

Were any Aclaris (ACRS) shares bought or sold on the open market in this Form 4?

No open-market purchases or sales are reported. The filing shows equity granted as compensation and the vesting of previously awarded restricted stock units into 11,580 common shares, without any reported market transactions by Vincent Milano.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILANO VINCENT

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		M		11,580	A	(1)	28,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.71	06/04/2026		A		42,350		(2)	06/03/2036	Common Stock	42,350	$0	42,350(3)	D
Restricted Stock Units	(1)	06/04/2026		A		10,987		(4)	(4)	Common Stock	10,987	$0	10,987(3)	D
Restricted Stock Units	(1)	06/05/2026		M			11,580	(5)	(5)	Common Stock	11,580	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

5. The shares underlying these restricted stock units vested on June 5, 2026.

	/s/ Matthew Rothman, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)